Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis.

Kovanda LL, Giamberardino C, McEntee L, Toffaletti DL, Franke KS, Bartuska A, Smilnak G, de Castro GC, Ripple K, Hope WW, Perfect JR.

Antimicrob Agents Chemother. 2019 Jun 17. pii: AAC.00546-19. doi: 10.1128/AAC.00546-19. [Epub ahead of print]

2.

Genotypic diversity and clinical outcome of cryptococcosis in renal transplant recipients in Brazil.

Ponzio V, Chen Y, Rodrigues AM, Tenor JL, Toffaletti DL, Medina-Pestana JO, Colombo AL, Perfect JR.

Emerg Microbes Infect. 2019;8(1):119-129. doi: 10.1080/22221751.2018.1562849.

3.

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus.

Shaw KJ, Schell WA, Covel J, Duboc G, Giamberardino C, Kapoor M, Moloney M, Soltow QA, Tenor JL, Toffaletti DL, Trzoss M, Webb P, Perfect JR.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00523-18. doi: 10.1128/AAC.00523-18. Print 2018 Aug.

4.

Structural and In Vivo Studies on Trehalose-6-Phosphate Synthase from Pathogenic Fungi Provide Insights into Its Catalytic Mechanism, Biological Necessity, and Potential for Novel Antifungal Drug Design.

Miao Y, Tenor JL, Toffaletti DL, Maskarinec SA, Liu J, Lee RE, Perfect JR, Brennan RG.

MBio. 2017 Jul 25;8(4). pii: e00643-17. doi: 10.1128/mBio.00643-17.

5.

Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the mechanisms of substrate recognition and catalysis.

Miao Y, Tenor JL, Toffaletti DL, Washington EJ, Liu J, Shadrick WR, Schumacher MA, Lee RE, Perfect JR, Brennan RG.

Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7148-53. doi: 10.1073/pnas.1601774113. Epub 2016 Jun 15.

6.

The Cryptococcus neoformans transcriptome at the site of human meningitis.

Chen Y, Toffaletti DL, Tenor JL, Litvintseva AP, Fang C, Mitchell TG, McDonald TR, Nielsen K, Boulware DR, Bicanic T, Perfect JR.

MBio. 2014 Feb 4;5(1):e01087-13. doi: 10.1128/mBio.01087-13.

7.

Nitrogen source-dependent capsule induction in human-pathogenic cryptococcus species.

Frazzitta AE, Vora H, Price MS, Tenor JL, Betancourt-Quiroz M, Toffaletti DL, Cheng N, Perfect JR.

Eukaryot Cell. 2013 Nov;12(11):1439-50. doi: 10.1128/EC.00169-13. Epub 2013 Aug 23.

8.

Brain inositol is a novel stimulator for promoting Cryptococcus penetration of the blood-brain barrier.

Liu TB, Kim JC, Wang Y, Toffaletti DL, Eugenin E, Perfect JR, Kim KJ, Xue C.

PLoS Pathog. 2013;9(4):e1003247. doi: 10.1371/journal.ppat.1003247. Epub 2013 Apr 4.

9.

Identification of genes from the fungal pathogen Cryptococcus neoformans related to transmigration into the central nervous system.

Tseng HK, Liu CP, Price MS, Jong AY, Chang JC, Toffaletti DL, Betancourt-Quiroz M, Frazzitta AE, Cho WL, Perfect JR.

PLoS One. 2012;7(9):e45083. doi: 10.1371/journal.pone.0045083. Epub 2012 Sep 20.

10.

Virulence factors identified by Cryptococcus neoformans mutant screen differentially modulate lung immune responses and brain dissemination.

He X, Lyons DM, Toffaletti DL, Wang F, Qiu Y, Davis MJ, Meister DL, Dayrit JK, Lee A, Osterholzer JJ, Perfect JR, Olszewski MA.

Am J Pathol. 2012 Oct;181(4):1356-66. doi: 10.1016/j.ajpath.2012.06.012. Epub 2012 Jul 28.

11.

Pleiotropic effects of deubiquitinating enzyme Ubp5 on growth and pathogenesis of Cryptococcus neoformans.

Fang W, Price MS, Toffaletti DL, Tenor J, Betancourt-Quiroz M, Price JL, Pan WH, Liao WQ, Perfect JR.

PLoS One. 2012;7(6):e38326. doi: 10.1371/journal.pone.0038326. Epub 2012 Jun 14.

12.

Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host.

Price MS, Betancourt-Quiroz M, Price JL, Toffaletti DL, Vora H, Hu G, Kronstad JW, Perfect JR.

MBio. 2011 Jun 7;2(3):e00103-11. doi: 10.1128/mBio.00103-11. Print 2011.

13.

Survival defects of Cryptococcus neoformans mutants exposed to human cerebrospinal fluid result in attenuated virulence in an experimental model of meningitis.

Lee A, Toffaletti DL, Tenor J, Soderblom EJ, Thompson JW, Moseley MA, Price M, Perfect JR.

Infect Immun. 2010 Oct;78(10):4213-25. doi: 10.1128/IAI.00551-10. Epub 2010 Aug 9.

14.

Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target.

Chayakulkeeree M, Rude TH, Toffaletti DL, Perfect JR.

Antimicrob Agents Chemother. 2007 Oct;51(10):3537-45. Epub 2007 Aug 13.

15.

Cryptococcus neoformans mitochondrial genomes from serotype A and D strains do not influence virulence.

Toffaletti DL, Nielsen K, Dietrich F, Heitman J, Perfect JR.

Curr Genet. 2004 Oct;46(4):193-204. Epub 2004 Aug 7.

PMID:
15309505
16.

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK Jr, Bartroli J, Perfect JR.

Antimicrob Agents Chemother. 2004 Feb;48(2):384-7.

17.

Cryptococcus neoformans gene expression during experimental cryptococcal meningitis.

Steen BR, Zuyderduyn S, Toffaletti DL, Marra M, Jones SJ, Perfect JR, Kronstad J.

Eukaryot Cell. 2003 Dec;2(6):1336-49.

18.

Identification of App1 as a regulator of phagocytosis and virulence of Cryptococcus neoformans.

Luberto C, Martinez-Mariño B, Taraskiewicz D, Bolaños B, Chitano P, Toffaletti DL, Cox GM, Perfect JR, Hannun YA, Balish E, Del Poeta M.

J Clin Invest. 2003 Oct;112(7):1080-94.

19.

Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates.

Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J.

Infect Immun. 2003 Sep;71(9):4831-41.

20.

Regulation of cytochrome c oxidase subunit 1 (COX1) expression in Cryptococcus neoformans by temperature and host environment.

Toffaletti DL, Del Poeta M, Rude TH, Dietrich F, Perfect JR.

Microbiology. 2003 Apr;149(Pt 4):1041-9.

PMID:
12686646
21.

Relationship of the glyoxylate pathway to the pathogenesis of Cryptococcus neoformans.

Rude TH, Toffaletti DL, Cox GM, Perfect JR.

Infect Immun. 2002 Oct;70(10):5684-94.

22.

Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans.

Luberto C, Toffaletti DL, Wills EA, Tucker SC, Casadevall A, Perfect JR, Hannun YA, Del Poeta M.

Genes Dev. 2001 Jan 15;15(2):201-12.

23.

Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.

Del Poeta M, Toffaletti DL, Rude TH, Dykstra CC, Heitman J, Perfect JR.

Genetics. 1999 May;152(1):167-78.

24.

Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein.

del Poeta M, Toffaletti DL, Rude TH, Sparks SD, Heitman J, Perfect JR.

Infect Immun. 1999 Apr;67(4):1812-20.

25.

A glucan synthase FKS1 homolog in cryptococcus neoformans is single copy and encodes an essential function.

Thompson JR, Douglas CM, Li W, Jue CK, Pramanik B, Yuan X, Rude TH, Toffaletti DL, Perfect JR, Kurtz M.

J Bacteriol. 1999 Jan;181(2):444-53.

26.

Biochemical role of the Cryptococcus neoformans ADE2 protein in fungal de novo purine biosynthesis.

Firestine SM, Misialek S, Toffaletti DL, Klem TJ, Perfect JR, Davisson VJ.

Arch Biochem Biophys. 1998 Mar 1;351(1):123-34.

PMID:
9500840
27.

Study of Cryptococcus neoformans actin gene regulation with a beta-galactosidase-actin fusion.

Toffaletti DL, Perfect JR.

J Med Vet Mycol. 1997 Sep-Oct;35(5):313-20.

PMID:
9402523
28.

Calcineurin is required for virulence of Cryptococcus neoformans.

Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J.

EMBO J. 1997 May 15;16(10):2576-89.

29.

Dominant selection system for use in Cryptococcus neoformans.

Cox GM, Toffaletti DL, Perfect JR.

J Med Vet Mycol. 1996 Nov-Dec;34(6):385-91.

PMID:
8971627
30.

Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans.

Lodge JK, Jackson-Machelski E, Toffaletti DL, Perfect JR, Gordon JI.

Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12008-12.

32.

Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA.

Toffaletti DL, Rude TH, Johnston SA, Durack DT, Perfect JR.

J Bacteriol. 1993 Mar;175(5):1405-11.

33.

Efficacy of immune therapy in early experimental Naegleria fowleri meningitis.

Lallinger GJ, Reiner SL, Cooke DW, Toffaletti DL, Perfect JR, Granger DL, Durack DT.

Infect Immun. 1987 May;55(5):1289-93.

34.

Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids.

Toffaletti DL, Darrow TL, Scott DW.

J Immunol. 1983 Jun;130(6):2982-6.

PMID:
6189910
35.

Modulation of lymphocyte functions by group A streptococcal membrane.

Toffaletti DL, Schwab JH.

Cell Immunol. 1979 Jan;42(1):3-17. No abstract available.

PMID:
373888

Supplemental Content

Loading ...
Support Center